AP01
AssetAlso pirfenidone, AMR-69, NSC-748456, Esbriet
Inhaled formulation of pirfenidone targeting fibrosis pathway.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 11
- Indications
- 2
- Trials
- 1
- Developer
Indications
11Hypersensitivity pneumonitis
Phase 2, Active not recruiting, NCT06329401, clinicaltrials.gov, 7 Oct 2026
Idiopathic pulmonary fibrosis
Phase 2, Recruiting, NCT06951217, clinicaltrials.gov, 7 Oct 2026
Interstitial lung disease
Phase 2, Active not recruiting, NCT06329401, clinicaltrials.gov, 7 Oct 2026
8 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials2
- Evidence for its targets1
- Competitors12
- Aging relevance1
- Signals9
Every asset’s record: target, stage, trials and the evidence behind it.